Hypertensive Kidney Disease

  • Xiaobing JiEmail author


Hypertensive kidney disease is defined as the damage to the kidney resulted from chronic high blood pressure (BP), which is pathologically classified as benign and malignant arteriolar nephrosclerosis. Given the increasing morbidity and mortality in patients with hypertensive kidney disease, therapeutic strategies for controlling BP and maximal reducing albuminuria are needed for delaying the progression of hypertensive nephropathy to end-stage renal disease. Most individuals with hypertensive kidney disease require combined use of three or more antihypertensive medications. Weight loss, exercise, and restriction on salt and alcohol intake may aid in BP control. The early recognition and adoption of potent approach to evaluate and manage patients with resistant hypertension may be effective strategies to achieve the BP targets. The malignant hypertension is life-threatening and requires immediate BP reduction for preventing irreversible target organ damage.


  1. 1.
    Botdorf J, Chaudhary K, Whaley-Connell A. Hypertension in cardiovascular and kidney disease. Cardiorenal Med. 2011;1:183–92.CrossRefGoogle Scholar
  2. 2.
    Segura J, Ruilope L. Hypertension in moderate-to-severe nondiabetic CKD patients. Adv Chronic Kidney Dis. 2011;18:23–7.CrossRefGoogle Scholar
  3. 3.
    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefGoogle Scholar
  4. 4.
    Kopp JB. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens. 2013;22(3):266–72.CrossRefGoogle Scholar
  5. 5.
    Freedman BI, Cohen AH. Hypertension-attributed nephropathy: what's in a name? Nat Rev Nephrol. 2016;12(1):27–36.CrossRefGoogle Scholar
  6. 6.
    Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT)—importance then and now. JAMA. 2008;300(11):1343–5.CrossRefGoogle Scholar
  7. 7.
    Luft FC. Hypertensive nephrosclerosis-a cause of end-stage renal disease? Nephrol Dial Transplant. 2000;15(10):1515–7.CrossRefGoogle Scholar
  8. 8.
    Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother. 2010;11(16):2675–86.CrossRefGoogle Scholar
  9. 9.
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.CrossRefGoogle Scholar
  10. 10.
    Shlipak MG, Matsushita K, Ärnlöv J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369(10):932–43.CrossRefGoogle Scholar
  11. 11.
    Shlipak MG, Ix JH, Bibbins-Domingo K, et al. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med. 2008;121(1):50–7.CrossRefGoogle Scholar
  12. 12.
    Seccia TM, Caroccia B, Calò LA. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35(2):205–12.CrossRefGoogle Scholar
  13. 13.
    Parati G, Stergiou G, O'Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359–66.CrossRefGoogle Scholar
  14. 14.
    Kidney Disease. Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.CrossRefGoogle Scholar
  15. 15.
    Bloch MJ. The dietary approaches to stop hypertension (DASH) diet-promise unmet. J Am Soc Hypertens. 2017;11(6):323–4.CrossRefGoogle Scholar
  16. 16.
    Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association professional education Committee of the Council for high blood pressure research. Circulation. 2008;117(25):e510–26.CrossRefGoogle Scholar
  17. 17.
    Braam B, Taler SJ, Rahman M, et al. Recognition and management of resistant hypertension. Clin J Am Soc Nephrol. 2017;12(3):524–35.CrossRefGoogle Scholar
  18. 18.
    Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol. 1998;9(1):133–42.PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Division of NephrologyNanjing First Hospital, Nanjing Medical UniversityNanjingChina

Personalised recommendations